Shots:

• Abbott to get non-exclusive license rights for Banyan’s TBI biomarkers- including Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) kit to utilize it on its laboratory instruments
• The focus of the agreement is to develop TBI assessment blood test for the patient with traumatic brain injury in the US and worldwide
• Banyan BTI is the first blood test used for identification of biomarkers GFAP and UCH-L1 released from the brain and consists of two test kits Banyan GFAP and Banyan UCH-L1 providing ease to physicians to detect TBIs 

Ref: Business Wire | Image:  Abbott